Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Legend Biotech CorporationNASDAQ: LEGN
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses declines year over year
Q3 FY2026 operating expenses of $165.1M fell 17.6% year over year, behind the -0.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 14.2% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- Operating expenses amounted to 73.6% of revenue in FY2025, down 37.3 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -17.6% toward the trailing-twelve-month pace of -0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 757.3M USD
- Year-over-year change
- +8.8%
- 4-year CAGR
- +13.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 757.3M | +8.8% |
| FY2024 | 2024-12-31 | 695.9M | +19.9% |
| FY2023 | 2023-12-31 | 580.41M | +14.4% |
| FY2022 | 2022-12-31 | 507.26M | +10.0% |
| FY2021 | 2021-12-31 | 461.11M | — |
Operating Expenses vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 operating expenses of $740.02M is the highest of the 11 companies compared; the peer median is $107.36M.
- Its year-over-year change of -0.1% is the 3rd highest of 11, against a peer median of -12.4%.
- Operating expenses amounts to 54.5% of revenue for LEGN, versus a peer median of 766.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $740.02M | -0.1% | +14.3% | 54.5% | |
| LTM Mar 2026 | $254.35M | -11.1% | +20.4% | 274.7% | |
| LTM Mar 2026 | $189.56M | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $140.97M | +26.8% | +7.2% | 1258.3% | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $112.97M | -32.5% | -15.4% | — | |
| LTM Mar 2026 | $101.75M | +11.1% | -1.4% | 149.4% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $82.81M | -13.0% | -1.4% | 183.7% | |
| LTM Mar 2026 | $80.29M | -7.3% | -1.7% | 4523.5% | |
| LTM Mar 2026 | $28.55M | -83.6% | -4.9% | 123.4% | |
| Peer median (excluding LEGN) | $107.36M | -12.4% | -3.3% | 766.5% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| Weighted Avg Shares | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
| Weighted Avg Shares (Diluted) | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.